Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 165

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Feasibility and Accuracy of Bioelectric Impedance Analysis in Estimating Skeletal Muscle Mass in Older Adults with Multiple Myeloma

Apoorva Doshi, Abigail Tucker, Gayathri Ravi, Susan Bal, Kelly Godby, William Evans, Mahalakshmi Shubha Shankaran, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2024) 144 (Supplement 1): 6963.

https://doi.org/10.1182/blood-2024-201688

Published: 2024

Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Blood (2024) 144 (Supplement 1): 677.

https://doi.org/10.1182/blood-2024-198403

Published: 2024

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Blood (2024) 144 (Supplement 1): 495.

https://doi.org/10.1182/blood-2024-200181

Published: 2024

Journal Articles

Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation

Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai Dholaria, Smith Giri, Saurabh Chhabra, Susan Bal, Kelly Godby, Gayathri Ravi, Rebecca W. Silbermann, Natalie Callander

Blood (2024) 144 (Supplement 1): 363.

https://doi.org/10.1182/blood-2024-201914

Published: 2024

Journal Articles

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Susan Bal, Myo Htut, Jesús G. Berdeja, Larry D Anderson, Jr., Adriana Rossi, Tara Gregory, Thomas G Martin, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Omar Nadeem

Blood (2024) 144 (Supplement 1): 2069.

https://doi.org/10.1182/blood-2024-203279

Published: 2024

Journal Articles

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Mayur S. Narkhede, Antonio Di Stasi, Lauren Kelly Shea, Susan Bal, Gayathri Ravi, Gaurav Goyal, Pamela Hardwick, Smith Giri, Donna Salzman, Ravi Bhatia, Luciano J. Costa, Amitkumar Mehta

Blood (2024) 144 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2024-205205

Published: 2024

Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Blood (2024) 144 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2024-199542

Published: 2024

Journal Articles

MRD Testing in Multiple Myeloma: Modeling the Potential Clinical and Economic Outcomes Based on the Master Trial

David Elsea, Josh J Carlson, Benjamin Eckert, Anthony Hewitt, Luciano J. Costa

Blood (2024) 144 (Supplement 1): 5028.

https://doi.org/10.1182/blood-2024-198502

Published: 2024

Journal Articles

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Blood (2024) 144 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2024-201783

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Blood (2024) 144 (Supplement 1): 594.

https://doi.org/10.1182/blood-2024-200300

Published: 2024

Journal Articles

Factors Associated with Post-Transplant Complications Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Apoorva Doshi, Gayathri Ravi, Susan Bal, Supriya Maheshwari, Kelly Godby, Luciano J. Costa, Joshua Richman, Grant Williams, Smita Bhatia, Smith Giri

Blood (2024) 144 (Supplement 1): 5145.

https://doi.org/10.1182/blood-2024-201737

Published: 2024

Journal Articles

Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)

Smith Giri, Binod Dhakal, Natalie Callander, Eva Medvedova, Kelly Godby, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca W. Silbermann, Luciano J. Costa

Blood (2024) 144 (Supplement 1): 257.

https://doi.org/10.1182/blood-2024-205611

Published: 2024

Journal Articles

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 922.

https://doi.org/10.1182/blood-2024-201356

Published: 2024

Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano J. Costa, Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Sarasa M.A. Johnson, Francis Vekeman, Patrick Hlavacek, Aster Meche, Paul Cislo, David Hughes, Guido Nador, Marco DiBonaventura

Blood (2024) 144 (Supplement 1): 2401.

https://doi.org/10.1182/blood-2024-203920

Published: 2024

Journal Articles

Longitudinal Trajectories of Patient-Reported Outcomes Among Older Adults with Multiple Myeloma (MM) Following Autologous Stem Cell Transplantation (ASCT)

Victoria Badia, Apoorva Doshi, Gayathri Ravi, Susan Bal, Kelly Godby, Donna Murdaugh, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2024) 144 (Supplement 1): 2387.

https://doi.org/10.1182/blood-2024-205712

Published: 2024

Journal Articles

Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial

Natalie Callander, Gayathri Ravi, Rebecca W. Silbermann, Zhubin J. Gahvari, Eva Medvedova, Bhagirathbhai Dholaria, Naresh Bumma, Doris K. Hansen, Everette M Colquette, Pamela Hardwick, Luciano J. Costa

Blood (2024) 144 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2024-210652

Published: 2024

Journal Articles

Real World Evidence on Patient Reported Outcomes Among Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Regimens in Frontline (1L)

Smith Giri, Liton Francisco, Nicole Rafalko, Niodita Gupta-Werner, Joshua Richman, Smita Bhatia, Kelly Godby, Gayathri Ravi, Susan Bal, Marjohn Armoon, Rohan Medhekar, Luciano J. Costa

Blood (2024) 144 (Supplement 1): 5151.

https://doi.org/10.1182/blood-2024-203431

Published: 2024

NARROW

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Feasibility and Accuracy of Bioelectric Impedance Analysis in Estimating Skeletal Muscle Mass in Older Adults with Multiple Myeloma

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

MRD Testing in Multiple Myeloma: Modeling the Potential Clinical and Economic Outcomes Based on the Master Trial

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Factors Associated with Post-Transplant Complications Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Longitudinal Trajectories of Patient-Reported Outcomes Among Older Adults with Multiple Myeloma (MM) Following Autologous Stem Cell Transplantation (ASCT)

Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial

Real World Evidence on Patient Reported Outcomes Among Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Regimens in Frontline (1L)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only